Celgene, GlobeImmune deal
GlobeImmune extended the option period for Celgene to license pancreatic cancer product GI-4000, according to GlobeImmune's updated S-1 registration statement filed on Aug. 16. Celgene will now have until after GlobeImmune delivers data from the Phase II portion of a planned Phase II/III trial, which is slated to begin next year. Celgene said the previous option period would have expired after a review of final data from the ongoing Phase IIb trial of GI-4000 to treat pancreatic cancer. In exchange, Celgene agreed to increase the amount of royalties for which GlobeImmune is eligible and agreed to purchase $4.9 million of GlobeImmune shares by March 31, 2013. GlobeImmune said Celgene has expressed interest in purchasing the shares during GlobeImmune's planned IPO. Celgene received the option to license exclusive, worldwide rights to all of GlobeImmune's oncology candidates under a 2009 deal (see BioCentury, May 18, 2009). ...